These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15383924)

  • 1. Treatment of osteoporosis in men.
    Orwoll ES
    Calcif Tissue Int; 2004 Aug; 75(2):114-9. PubMed ID: 15383924
    [No Abstract]   [Full Text] [Related]  

  • 2. Issues in designing and testing a "cure" for osteoporosis.
    Cummings S
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):408. PubMed ID: 15758283
    [No Abstract]   [Full Text] [Related]  

  • 3. [What to use to treat osteoporosis?].
    Välimäki MJ
    Duodecim; 2003; 119(24):2409-12. PubMed ID: 14870501
    [No Abstract]   [Full Text] [Related]  

  • 4. Summary--curing osteoporosis.
    Cummings S
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):409. PubMed ID: 15758284
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteoporosis in men.
    Prelevic GM
    J R Soc Med; 2001 Dec; 94(12):620-3. PubMed ID: 11733587
    [No Abstract]   [Full Text] [Related]  

  • 6. The anabolic effects of parathyroid hormone.
    Rubin MR; Cosman F; Lindsay R; Bilezikian JP
    Osteoporos Int; 2002; 13(4):267-77. PubMed ID: 12030541
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocrine regulation of bone turnover in men.
    Meier C; Liu PY; Handelsman DJ; Seibel MJ
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):603-16. PubMed ID: 16343093
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteoporosis in men.
    Seeman E
    Osteoporos Int; 1999; 9 Suppl 2():S97-S110. PubMed ID: 10525732
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone turnover-sex hormone-parathyroid hormone interrelationships in postmenopausal osteoporosis.
    Riggs B; Jowsey J; Kelly PJ; Arnaud CD
    Boll Soc Ital Biol Sper; 1973 Jul; 49(12):732-7. PubMed ID: 4364781
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inhibition of progression of decreasing bone mass and manifest osteoporosis].
    Ringe JD
    Internist (Berl); 1993 Apr; 34(4):300-6. PubMed ID: 8486473
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant parathyroid hormone in the management of osteoporosis.
    Compston J
    Calcif Tissue Int; 2005 Aug; 77(2):65-71. PubMed ID: 16059774
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drugs in development for the treatment of osteoporosis: Incadronate].
    Ohsawa M; Soda M; Mizunuma H
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():538-43. PubMed ID: 11979952
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of osteoporosis in chronically ill children.
    Munns CF; Cowell CT
    J Musculoskelet Neuronal Interact; 2005; 5(3):262-72. PubMed ID: 16172517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parathyroid hormone for osteroporsis: why and who to treat?].
    Ferrari S; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth and age-related origins of bone fragility in men.
    Seeman E
    Calcif Tissue Int; 2004 Aug; 75(2):100-9. PubMed ID: 15383923
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 18. [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
    MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529718
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recombinant human parathyroid hormone--new perspectives for anabolic therapy of osteoporosis].
    Miazgowski T; Stefański A
    Pol Arch Med Wewn; 2004 Oct; 112(4):1249-54. PubMed ID: 15773439
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.